Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy drug and related business to France’s Servier for up to $2.65 billion.
The French drugmaker will secure global rights to the U.S.-based biotech’s candidate, sevasemten, along with associated intellectual property, clinical data and staff supporting the program for $1.55 billion in upfront cash. Edgewise will also be e… [833 chars]
Source: Reuters | Published: 2026-06-01T12:34:59Z
Credit: Reuters
